Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

VEL-101

Phase 2Small molecule

VVeloxis Pharmaceuticals

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Transplantation, KidneyRecruiting

Transplantation, KidneyPhase 2

Recruiting

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Transplantation, Kidney

NCT07290777

Clinical

Trials by Indication[1]

Tics1 trial

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

Completed·VVeloxis Pharmaceuticals·Phase 1·NCT05238493·60 enrolled

Transplantation, Kidney1 trial

A Phase 2, Randomized, Partially Blinded, Controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VEL-101 in Kidney Transplant Recipients.

Recruiting·VVeloxis Pharmaceuticals·Phase 2·NCT07290777·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for VEL-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VEL-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VEL-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Veloxis Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVeloxis Pharmaceuticals

Related News